Related Experiment Video
Updated: Oct 5, 2026

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
Published on: September 29, 2019
Lipopolysaccharide: neutralization by polymyxin B shuts down the signaling pathway of nuclear factor kappaB in
1First Department of Surgery, Shiga University of Medical Science, Seta-tsukinowa-cho, Otsu-city, Shiga, 520-2192, Japan. tsuzukih@smile.ocn.ne.jp
Background:
There have been many studies on anti-lipopolysaccharide (LPS) agents and LPS-neutralizing agents; however, there have been no reports on the changes in clinical status and mediators that occur when these agents are used. Polymyxin (PMX) (treatment using a column containing polymyxin B-immobilized fiber) removed circulating endotoxin, and reduced various cytokines within 120 min, even in patients with high levels of plasma cytokines. Our purpose was examine the mechanisms of PMX treatment by which plasma cytokines are reduced by endotoxin neutralization with polymyxin B, even during therapy for sepsis and/or endotoxin shock.
Methods:
We studied the interaction between nuclear factor kappaB (NF-kappaB) binding activity and tumor necrosis factor alpha (TNF-alpha) secretion in an experimental system using LPS-stimulated human peripheral blood mononuclear cells (PBMCs), after neutralization of LPS with polymyxin B. PBMCs were incubated with LPS in vitro, and TNF-alpha secretion and NF-kappaB activation were assessed. We then studied the changes in NF-kappaB activation and TNF-alpha secretion when both polymyxin B and LPS were added simultaneously and when polymyxin B was added after 30 or 120 min of incubation with LPS.
Results:
Immediate inhibition of NF-kappaB binding activity and suppression of TNF-alpha secretion were observed after LPS neutralization with polymyxin B regardless of whether PBMCs were already producing TNF-alpha.
Conclusions:
These findings may indicate one of the mechanisms operating in the clinical changes that occur after circulating endotoxin removal, and are likely to have therapeutic value, even for patients with high proinflammatory cytokine levels.
Insights
Polymyxin B (PMX) neutralizes lipopolysaccharide (LPS), rapidly reducing inflammatory cytokines like tumor necrosis factor alpha (TNF-alpha) by inhibiting nuclear factor kappaB (NF-kappaB) activation. This endotoxin neutralization offers therapeutic potential for sepsis and endotoxin shock.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Lipopolysaccharide (LPS) is a key endotoxin implicated in sepsis and endotoxin shock.
- Polymyxin B (PMX) is an agent used to neutralize LPS, but its precise mechanisms for reducing clinical mediators remain unclear.
- Previous studies highlight PMX's ability to reduce circulating endotoxin and cytokines, even in severe cases.
Purpose of the Study:
- To investigate the mechanisms by which PMX treatment reduces plasma cytokines through endotoxin neutralization.
- To examine the relationship between PMX, LPS, and the subsequent modulation of inflammatory mediators.
Main Methods:
- Studied the interaction between nuclear factor kappaB (NF-kappaB) binding activity and tumor necrosis factor alpha (TNF-alpha) secretion in vitro.
- Utilized LPS-stimulated human peripheral blood mononuclear cells (PBMCs) and assessed TNF-alpha secretion and NF-kappaB activation.
- Administered polymyxin B simultaneously with LPS or at 30 and 120 minutes post-LPS stimulation.
Main Results:
- Immediate inhibition of NF-kappaB binding activity was observed upon LPS neutralization with polymyxin B.
- Suppression of TNF-alpha secretion was achieved regardless of the timing of polymyxin B administration relative to LPS stimulation.
- These effects occurred even when PBMCs were already producing TNF-alpha.
Conclusions:
- Polymyxin B's rapid inhibition of NF-kappaB activation and TNF-alpha secretion provides a key mechanism for its clinical efficacy.
- Endotoxin neutralization by PMX is effective even in patients with high levels of pro-inflammatory cytokines.
- These findings support the therapeutic value of PMX in managing sepsis and endotoxin shock.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway
Formation of Lipopolysaccharides
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Viral Protein Synthesis
Regulation of Nuclear Protein Sorting
